Jens Bollerslev

ORCID: 0000-0002-0654-4610
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pituitary Gland Disorders and Treatments
  • Growth Hormone and Insulin-like Growth Factors
  • Bone Metabolism and Diseases
  • Bone health and treatments
  • Parathyroid Disorders and Treatments
  • Bone health and osteoporosis research
  • Gestational Diabetes Research and Management
  • Pregnancy and preeclampsia studies
  • Adrenal and Paraganglionic Tumors
  • Vitamin D Research Studies
  • Birth, Development, and Health
  • Genetic Syndromes and Imprinting
  • Adrenal Hormones and Disorders
  • Bone and Joint Diseases
  • Nutrition and Health in Aging
  • Biomarkers in Disease Mechanisms
  • Thyroid and Parathyroid Surgery
  • Ophthalmology and Eye Disorders
  • Dermatological and Skeletal Disorders
  • Bariatric Surgery and Outcomes
  • Wnt/β-catenin signaling in development and cancer
  • Adipokines, Inflammation, and Metabolic Diseases
  • Glioma Diagnosis and Treatment
  • Digestive system and related health
  • Bone and Dental Protein Studies

Oslo University Hospital
2016-2025

University of Oslo
2016-2025

Faculty (United Kingdom)
2010-2019

Hospital for Special Surgery
2017

Cornell University
2017

University Hospital of North Norway
2014

UiT The Arctic University of Norway
2014

Endocrine Society
2011-2013

Health Net
2013

National University Hospital
1997-2011

Hypoparathyroidism (HypoPT) is a rare (orphan) endocrine disease with low calcium and inappropriately (insufficient) circulating parathyroid hormone levels, most often in adults secondary to thyroid surgery. Standard treatment activated vitamin D analogues supplementation not replacement of the lacking hormone, as other hormonal deficiency states. The purpose this guideline provide clinicians guidance on monitoring chronic HypoPT who do have end-stage renal disease. We intend draft practical...

10.1530/eje-15-0628 article EN European Journal of Endocrinology 2015-07-10

Primary adrenal insufficiency [Addison's disease (AD)] is rare, and systematic studies are few, mostly conducted on small patient samples. We aimed to determine the clinical, immunological, genetic features of a national registry-based cohort.Patients with AD identified through nationwide search diagnosis registries were invited participate in survey clinical features, health-related quality life (HRQoL), autoantibody assays, human leukocyte antigen (HLA) class II typing.Of 664 registered...

10.1210/jc.2009-1368 article EN The Journal of Clinical Endocrinology & Metabolism 2009-10-27

The clinical presentation of primary hyperparathyroidism (pHPT) has changed during the last half century, and diagnosis is now more often made by chance in patients with no specific symptoms.The present study a randomized, controlled trial that investigates effects parathyroidectomy or medical observation mild asymptomatic pHPT on morbidity quality life (QoL).A total 191 (26 men) [mean age 64.2 +/- 7.4 (sd) yr] were recruited randomized to (serum calcium level 2.69 0.08 mmol/liter) surgery...

10.1210/jc.2006-1836 article EN The Journal of Clinical Endocrinology & Metabolism 2007-02-07

Asymptomatic primary hyperparathyroidism (PHPT) is a common clinical problem. The only available definitive therapy parathyroidectomy, which appropriate to consider in all patients. purpose of this report provide an update on calcium and vitamin D supplementation medical management for those patients with PHPT who cannot or do not want undergo surgery.Questions were developed by the International Task Force PHPT. A comprehensive literature search was undertaken, relevant articles published...

10.1210/jc.2014-1417 article EN The Journal of Clinical Endocrinology & Metabolism 2014-08-27

OBJECTIVE Sodium–glucose cotransporter 2 (SGLT2) inhibitors have lately become the recommended treatment in patients with type diabetes and high cardiovascular risk. Patients posttransplant mellitus (PTDM) also The aim of this study was to investigate safety efficacy empagliflozin renal transplant recipients PTDM. RESEARCH DESIGN AND METHODS Forty-nine were included an investigator-initiated, single-center, prospective, double-blind randomized receive either 10 mg or placebo once daily for...

10.2337/dc19-0093 article EN Diabetes Care 2019-03-12

This European expert consensus statement provides recommendations for the diagnosis and management of primary hyperparathyroidism (PHPT), chronic hypoparathyroidism in adults (HypoPT), parathyroid disorders relation to pregnancy lactation. Specified areas interest unmet needs identified by experts at second ESE Educational Program Parathyroid Disorders (PARAT) 2019, were discussed during two virtual workshops 2021, subsequently developed working groups with specified areas. PHPT is a common...

10.1530/eje-21-1044 article EN cc-by European Journal of Endocrinology 2021-12-06

Abstract The 6th International Conference, “Controversies in Vitamin D,” was convened to discuss controversial topics, such as vitamin D metabolism, assessment, actions, and supplementation. Novel insights into mechanisms of action suggest links with conditions that do not depend only on reduced solar exposure or diet intake can be detected distinctive noncanonical metabolites. Optimal 25-hydroxyvitamin (25(OH)D) levels remain debated. Varying recommendations from different societies arise...

10.1210/endrev/bnae009 article EN cc-by Endocrine Reviews 2024-04-26

The autoimmune polyendocrine syndrome type I (APS I) is a rare disease that previously was difficult to diagnose. Autoantibody screening as well mutational analysis of the gene regulator (AIRE) are important diagnostic tools for this life-threatening syndrome.The objective study identify all patients with APS in Norway and correlate their clinical features autoantibody profiles mutations AIRE gene.We identified 36 Norwegian from 24 families (20 males, 16 females) during nationwide survey...

10.1210/jc.2006-1873 article EN The Journal of Clinical Endocrinology & Metabolism 2006-11-21

Context: Surgery is the primary treatment of acromegaly. However, it often fails to cure patient. New strategies that improve surgical outcome are needed. Objective: Our objective was investigate whether 6-month preoperative with octreotide improves in newly diagnosed acromegalic patients. Patients: During a 5-yr period (1999–2004), all patients between 18 and 80 yr age Norway were screened invited participate study. A total 62 included Preoperative Octreotide Treatment Acromegaly Research...

10.1210/jc.2008-0315 article EN The Journal of Clinical Endocrinology & Metabolism 2008-05-21

Objective Weight reduction improves several obesity-related health conditions. We aimed to compare the effect of bariatric surgery and comprehensive lifestyle intervention on type 2 diabetes cardiovascular risk factors. Design One-year controlled clinical trial (ClinicalTrials.gov identifier NCT00273104). Methods Morbidly obese subjects (19–66 years, mean ( s.d. ) body mass index 45.1 kg/m (5.6), 103 women) were treated with either Roux-en-Y gastric bypass n =80) or intensive at a...

10.1530/eje-10-0514 article EN European Journal of Endocrinology 2010-08-27

Genetic mutations in the LRP5 gene affect Wnt signaling and lead to changes bone mass humans. Our vivo vitro results show that activated mutation T253I of enhances osteogenesis inhibits adipogenesis. Inactivating T244M exerts opposite effects.Mutations co-receptor, LRP5, leading decreased or increased canonical signaling, result osteoporosis a high (HBM) phenotype, respectively. However, mechanisms whereby mutated causes are not known.We studied marrow composition iliac crest biopsies from...

10.1359/jbmr.070721 article EN Journal of Bone and Mineral Research 2007-08-06

Context Patients with primary adrenal insufficiency (Addison's disease) receive more glucococorticoids than the normal endogenous production, raising concern about adverse effects on bone.To determine i) of glucocorticoid replacement therapy bone, and ii) impact pharmacogenetics.A cross-sectional study two large Addison's cohorts from Norway (n=187) UK New Zealand (n=105).Bone mineral density (BMD) was measured; Z-scores represent comparison a reference population. Blood samples 187...

10.1530/eje-08-0880 article EN European Journal of Endocrinology 2009-03-13

The prevalence of vitamin D insufficiency and secondary hyperparathyroidism is high among morbidly obese subjects. Further, low serum levels 25-hydroxyvitamin (25 [OH]D) magnesium have been associated with increased risk the metabolic syndrome (MS), recently, a possible link between PTH MS has reported. Although it well known that synthesis secretion regulated by calcium, phosphate, 25(OH)D, less about clustered affiliation these parameters MS. We aimed to explore whether abnormal PTH,...

10.1186/1475-2840-8-7 article EN cc-by Cardiovascular Diabetology 2009-01-01

Introduction Birthweight is used as an indicator of intrauterine growth, and determinants birthweight are widely studied. Less known about deviating patterns growth in utero. We aimed to study the effects maternal characteristics on both fetal third trimester introduce placental weight a possible determinant trimester. Methods The STORK prospective cohort including 1031 healthy pregnant women Scandinavian heritage with singleton pregnancies. Maternal (age, parity, body mass index (BMI),...

10.1371/journal.pone.0039324 article EN cc-by PLoS ONE 2012-06-18

Mild primary hyperparathyroidism (pHPT) seems to have a good prognosis, and indications for active treatment (surgery) are widely discussed. The extraskeletal effects of PTH, such as insulin resistance, arterial hypertension, cardiovascular (CV) risk, may however be reversible by operation.Our aim was study biochemical markers bone turnover, indices the metabolic syndrome, various risk CV disease in patients with mild pHPT randomized observation without surgery or operative followed 2 yr.A...

10.1210/jc.2008-2742 article EN The Journal of Clinical Endocrinology & Metabolism 2009-04-08
Coming Soon ...